• Animal cells and systems
• /
• 제13권4호
• /
• pp.429-437
• /
• 2009

The control mechanism of gonadotropin-releasing hormone (GnRH) on gonadotropin (GTH) release was studied using cultured pituitary cell or cultured whole pituitary obtained from Testosterone (T) treated and control immature rainbow trout. The release of FSH was not changed by salmon type GnRH (sGnRH), chiken-II type (cGnRH-II), GnRH analogue ([des-$Gly^{10}D-Ala^6$] GnRH ethylamide) and GnRH antagonist ([Ac-3, 4-dehydro-$Pro^1$, D-p-F-$Phe^2$, D-$Trp^{3,6}$] GnRH) in cultured pituitary cells of T-treated and control fish. Indeed, FSH release was not also altered by sGnRH in cultured whole pituitary. All tested drugs had no effect on the release of LH in both culture systems of control fish. The levels of LH, in contrast, such as the pituitary content, basal release and responsiveness to GnRH were increased by T administration in both culture systems. In addition, the release of LH in response to sGnRH or cGnRH-II induced in a dose-dependent manner from cultured pituitary cells of T-treated fish, but which is not significantly different between in both GnRH at the concentration examined. Indeed, LH release was also increased by sGnRH in cultured whole pituitary of T-treated fish. GnRH antagonist suppressed the release of LH by sGnRH ($10^{-8}\;M$) and GnRH analogue ($10^{-8}\;M$) stimulation in a dose-dependent manner from cultured pituitary cells of T-treated fish, and which were totally inhibited by $10^{-7}\;M$ GnRH antagonist. These results indicate that the sensitivity of pituitary cells to GnRH is elevated probably through the T treatment, and that GnRH is involved in the regulation of LH release. GnRH-stimulated LH release is inhibited by GnRH antagonist in a dose-dependent manner. The effects of gonadal steroids on FSH levels are less clear.

• Clinical and Experimental Reproductive Medicine
• /
• 제18권1호
• /
• pp.1-11
• /
• 1991

• Tuberculosis and Respiratory Diseases
• /
• 제53권3호
• /
• pp.349-353
• /
• 2002

여러 국내외 논문에서 hormone 치료는 우수한 효과를 나타내었으나 치료 종료 후 객혈이 다시 발생하여 추가적인 수술을 받는 경우가 많았으며, GnRH analogue의 장점에도 불구하고 hormone 치료로 완치된 예는 대부분 danazol에 의한 경우가 많았다. 저자들이 경험한 환자는 월경과 동반된 객혈, 월경주기에 따라 변하는 방사선학전 변화와 GnRH analogue 치료에 대한 극적인 증상의 호전 등의 전형적인 소견으로 폐실질 자궁내막증에 의한 catamenial hemoptysis로 진단되었다. 6회의 hormone 치료 기간동안 임상양상의 호전을 보였고, 치료를 중단한 후에도 재발의 증거가 없는 상태로 외래를 다니고 있다.

• 한국양식학회지
• /
• 제9권3호
• /
• pp.205-213
• /
• 1996

한국산 메기의 경제적이고 효율적인 산란유도를 위한 연구로써 GnRH-a의 이용가능성에 대하여 검토하여 다음과 같은 결과를 얻었다. GnRH-a 처리된 메기의 산란유도율은 어체중 kg당 70 ${\mu}g$에서 $67\%$, 90 ${\mu}g$에서 $86\%,\;120{\mu}g$이상에서는 $100\%$로 나타났다. 호르몬 주사후 산란이 유도되기까지 대체로 $22\~25$시간이 소요되었다. 생식소중량지수(GSI)는 $100\%$의 산란유도율을 보인 120 ${\mu}g/kg$처리된 그룹에서 $23\~30\%$를 pseudo-GSI는 $18\~21\%$로 비교적 높고 고른 분포를 나타냈으며, 산란된 난의 수는 어체중 kg당 $58,000\~65,000$개 였다. 또한 수정률 및 부화율은 각각 $94\%$와 $81\%$로 나타났다. GnRH-a 처리에 따른 뇌하수체의 미세구조적 변화를 관찰한 바, 호르몬 주사전 성숙한 암컷 메기의 생식소자극호르몬 분비세포(gonadotrops)는 전자밀도가 높은 $150\~300$ nm 크기의 수 많은 소과립과 $800\~1000\;nm$의 전자밀도가 다소 낮은 소수의 대과립의 존재가 관찰되었다. 한편 호르몬주사후의 gonadotrops에서는 대소 과립들의 현저한 소실과 rER의 현저한 증가가 관찰되었는데, 이는 GnRH-a에 의해 생식소자극호르몬의 대량방출을 시사하는 것이다. 이상의 결과로부터 GnRH-a의 사용은 기존의 HCG 및 잉어뇌하수체 분말보다 적어도 $2\~3$ 배이상의 비용절감을 가져와 메기의 인공 종묘 생산에 매우 효과적이고 경제성이 있는 것으로 나타났다.

• 한국양식학회지
• /
• 제9권1호
• /
• pp.3-10
• /
• 1996

인간의 태반성 성선자극호르몬(HCG) 또는 성선자극호르몬-방출호르몬 유도체(GnRH-A)와 pimozide를 이용하여 산란시기의 암컷황복에서 인공 산란을 유도하였다. 호르몬 또는 호르몬유도체의 효과는 배란 후 인공수정시켜 수정율과 배체형성율 및 면역방사측정법으로 혈액의 plasma 내 성선자극호르몬(GTH) 양을 측정하여 결정하였다. 수정율과 배체형성율이 가장 좋은 HCG 농도는 어체중 kg 당 1,000 IU이었다. 또한 GnRH-A ($10\;{\mu}g/kg$)와 pimozide를 동시에 처리했을 때 수정율과 배체형성율이 좋은 pimozide의 농도는 5 mg/kg이었다. Pimozide(1, 5 mg/kg)를 단독으로 처리한 어류에서는 plasma 내 GTH양에 영향을 줄 수 없었지만, GnRH-A와 동시에 처리했을 때 GTH양은 현저히 증가되었다. GnRH-A와 pimozide 및 dopamine을 동시에 처리했을 때 혈액의 plasma 내 GTH양은 크게 감소되었다. 이상의 결과는 산란시기 또는 이시기이외에 황복의 뇌로부터 여러 가지 성선자극호르몬과 성선자극억제호르몬을 분비됨을 시사해 준다.

• 한국양식학회지
• /
• 제11권4호
• /
• pp.513-519
• /
• 1998

인간의 태반성 성선자극 호르몬(HCG) 또는 성선자극 호르몬-방출 호르몬 유도체(GnRH-a) 단독 주사와 HCG+GnRH-a, GnRH-a+prostaglandin E sub(2) (PGF sub(2)), GnRH-a+pimozide를 복합적으로 주사하여 성숙한 암컷 쏘가리에서 배란 유도 실험을 하였다. 호르몬과 유도체의 반응 효과는 배란후 인공 수정하여 수정율과 배체형성율을 측정하여 결정하였다. 일반적으로 GnRH-a 실험군이 HCG 실험군에 비해서 수정율과 배체형성율 및 부화율이 높았다. HCG(5,000 IU/kg)+(GnRH-a(10 ${\mu}$g), GnRH-a(10 ${\mu}$g/kg)+PG$F^2$(500 ng/kg) 및 GnRH-a(10 ${\mu}$g/kg)+pimozide(1-5 mg/kg)에서 89% 이상의 높은 부화율을 보였다. 본 연구에서 사용된 성성숙 호르몬과 자극물질로 처리된 모든 암컷에서 배란이 유도되었지만, HCG+GnRH-a+dopamine과 GnRH-a+PG$F_2$+indometacin 처리군에서는 배란이 억제되었다. 이들의 결과는 산란시기에 여러 가지 성성숙 호르몬과 관련된 호르몬과 성성숙 억제물질(GRIF)이 분비된다는 점을 시사한다.

• Clinical and Experimental Reproductive Medicine
• /
• 제19권2호
• /
• pp.175-179
• /
• 1992

The factors involved in the initial neoplastic transformation and subsquent growth of uterine fibroid are poorly understood. The reduction in uterine fibroid volume associated with the chronic administration of the mechanisms mediating the decrease in fibroid volume in GnRH-a treated patients are poorly defined. The purpose of this study was to determine the proliferating cell nuclear antigen(PCNA) in fibroid from-women pretreated with GnRH analogue(GnRH-a) compared with controls. Tissue was obtained from 16 premenopausal women with uterine fibroid who received GnRH-a(D-Trp6-GnRH) intramusculary every 28 days for four injections. The mean proliferating index(PI) in patients with uterine fibroids was $2.25{\pm}0.9$, and in controls was $8.82{\pm}1.8$(P<0.001). The proliferating index was not corrleated with the reduction of fibroid volume. In this clinical study, although hypoestrogenism may be the main factor that reduce the volume of fibroid, other factors are also considered to be involved in that process. And the regrowth of uterine fibroid may be affected by increased production of PCNA after stopping GnRH-a.

• 한국수정란이식학회지
• /
• 제25권4호
• /
• pp.287-290
• /
• 2010

On January 6, 2010, two months earlier than normal breeding season, a red fox vixen was implanted with synthetic GnRH analogue, Deslorelin. Blood was sampled every 2~3 days from the day of implant to identifying spermatozoa on stains of epithelial cells. Estradiol and progesterone were examined. Even though the vixen was in non-breeding season, she was mated by a male fox. Pregnancy was confirmed by canine pregnancy detection kit that detect relaxin released from placenta. Four healthy pups were born on March 9, 2010. This is the first report showing synthetic GnRH can activate ovarian function and lead to fertile estrus of red fox in non-breeding season.

• Animal cells and systems
• /
• 제4권3호
• /
• pp.287-292
• /
• 2000

The present work examined the role of gonadotropin-releasing hormone (GnRH) and dopaminergic drugs on the secretion of maturational gonadotropin (GTH II) in relation to testosterone m treatment. This study provides evidence that the plasma GTH II levels are increased by T treatment in precocious males, but not in the immature animal. In addition, GnRH analogue (GnRHa) alone significantly increased the plasma GTH II secretion in immature rainbow trout treated with T, as well as in T-treated and T-untreated precocious males. However, injection with either dopamine (DA) or domperidone (DOM; DA D2 receptor antagonist) alone did not alter the basal plasma GTH 11 secretion in all experimental groups. The secretion of GTH II in the T-treated precocious males was remarkably influenced by GnRHa or combination of dopaminergic drugs. Notably, the effects of dopaminergic drugs on GnRHa-induced GTH II secretion w8s prolonged by T in precocious males. In T-treated immature animals, GnRHa-induced GTH II secretion was Increased only by a dose DOM (10$\mu$g/g body n) but not by higher dose DOM (100$\mu$/g body wt). In the T-untreated immature rainbow trout, however, plasma GTH 11 secretion was not influenced by the same treatments. Therefore, these results indicate that DA may be acting indirectly by blocking the effect of GnRH on GTH II secretion in vivo. T may act to modulate the relative contribution by the stimulatory (GnRH) and inhibitory (DA) neuroendocrine factors, which would ultimately determine the pattern of GTH II secretion.

• 한국임상수의학회지
• /
• 제33권4호
• /
• pp.200-204
• /
• 2016

This study investigated whether presynchronization with GnRH 6 days before initiation of the Ovsynch program improved reproductive outcomes in dairy cows. Additionally, postponement of initiation of the Ovsynch program for cows during the metestrus phase by 5 days was investigated to determine if it improved reproductive outcomes. To accomplish this, 941 Holstein dairy cows with unknown estrous cycle were randomly allocated into an Ovsynch group (n = 768; $100{\mu}g$ gonadorelin [a GnRH analogue], $500{\mu}g$ of cloprostenol [$PGF_{2{\alpha}}$ analogue] seven days later, $100{\mu}g$ gonadorelin 56 h later and timed artificial insemination [AI] 16 h after) and a G6-Ovsynch (n = 173) that received $100{\mu}g$ GnRH followed by the Ovsynch program 6 days later. Additionally, 272 dairy cows with known estrous cycle (metestrus stage) received the Ovsynch 5 days later (Day 5-Ovsynch group, n = 272). The odds ratio (OR) for pregnancy was analyzed by logistic regression using the LOGISTIC procedure in SAS. The treatment group (p < 0.001) and AI season (p < 0.05) significantly affected the probability of pregnancy, whereas farm, cow parity, calving to AI interval, and body condition score had no affect (p > 0.05). The Day 5-Ovsynch group had a higher probability of pregnancy (OR: 1.71) than the Ovsynch group, while that of the G6-Ovsynch group was intermediate (p > 0.05). Cows inseminated during winter had a higher OR (1.39) than those inseminated during spring. Overall, additional GnRH treatment 6 days before the Ovsynch did not improve reproductive outcomes, whereas postponement of the initiation of Ovsynch by 5 days for cows during metestrus improved reproductive outcomes.